Prostate cancer remains one of the most common cancers affecting men worldwide, and while many cases respond well to early treatment, advanced forms of the disease can be far more difficult to manage. A major challenge has been finding effective therapies for aggressive subtypes that grow and spread quickly. One of these subtypes involves tumors with PTEN deficiency, a genetic change that makes cancer cells more aggressive and less responsive to standard hormone-based treatments.

In a significant step forward, the U.S. Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with abiraterone and prednisone as the first targeted therapy specifically for adults with PTEN‑deficient metastatic prostate cancer that is still sensitive to hormone-based treatment. This approval marks a major milestone in precision oncology and offers new hope for thousands of patients each year.

This blog post breaks down what this approval means, why PTEN deficiency matters, how Truqap works, and what patients and families should know about this new treatment option.

Understanding PTEN Deficiency and Why It Matters

PTEN is a gene that helps regulate cell growth. When PTEN is functioning normally, it acts as a tumor suppressor, keeping cell division in check. But when PTEN is missing or not working properly, cancer cells can grow faster, spread more easily, and become harder to control with standard therapies.

About 1 in 4 patients with metastatic androgen pathway modulation‑naive or sensitive (mAPMN/S) prostate cancer – previously known as metastatic hormone‑sensitive prostate cancer – have PTEN‑deficient tumors. These cancers tend to progress more quickly and are associated with worse outcomes.

Because PTEN deficiency can be identified through an FDA‑authorized test, doctors can now determine which patients may benefit from Truqap. This makes the treatment one of the first biomarker‑guided options for this specific prostate cancer subtype.

What Is Truqap?

Truqap (capivasertib) is an oral medication that blocks all three forms of AKT, a protein involved in cancer cell growth and survival. When AKT is overactive – which often happens in PTEN‑deficient tumors – cancer cells can multiply rapidly and resist treatment. By inhibiting AKT, Truqap helps slow or stop cancer growth at a molecular level.

Truqap is taken in combination with:

• Abiraterone, a hormone‑blocking drug that reduces androgen production
• Prednisone, a steroid that helps manage side effects and support treatment effectiveness

Together, these medications target both the hormonal drivers of prostate cancer and the molecular pathways that allow PTEN‑deficient tumors to thrive.

Who Is Eligible for This Treatment?

The FDA approval covers adults with:

• Metastatic prostate cancer
• Tumors that are PTEN‑deficient
• Disease that is still sensitive to hormone‑based therapy (mAPMN/S)

This group includes approximately 35,000 patients in the U.S. each year. Because PTEN deficiency is present in about 25 percent of these cases, roughly 8,000 to 9,000 patients annually may be candidates for Truqap.

A companion diagnostic test – the VENTANA PTEN (SP218) RxDx Assay – was approved alongside Truqap to help identify eligible patients.

What the Clinical Trial Showed

The FDA approval is based on results from the Phase 3 CAPItello‑281 trial, which enrolled 1,012 adults with newly diagnosed PTEN‑deficient metastatic prostate cancer. Participants were randomly assigned to receive either:

• Truqap plus abiraterone and prednisone
• A placebo plus abiraterone and prednisone

All patients also received standard androgen deprivation therapy.

Key Findings

• Risk reduction: Truqap reduced the risk of radiographic disease progression or death by 19 percent compared with the placebo combination.
• Progression‑free survival: Patients receiving Truqap had a median of 33.2 months without cancer worsening, compared with 25.7 months for the placebo group.
• Overall survival: Data were not mature at the time of analysis, meaning it was too early to determine long‑term survival differences.

These results show that Truqap can meaningfully delay cancer progression, giving patients more time before the disease worsens.

Why This Approval Is Important

This is the first time a therapy has been approved specifically for PTEN‑deficient metastatic prostate cancer. Until now, treatment options for this aggressive subtype were limited, and outcomes were often poor.

Experts emphasize that this approval highlights the importance of biomarker testing in prostate cancer. Identifying PTEN deficiency at diagnosis can help doctors choose the most effective treatment strategy from the start.

The approval also expands the role of precision medicine in prostate cancer, similar to how targeted therapies have transformed treatment for breast, lung, and other cancers.

How Truqap Works With Abiraterone and Prednisone

Truqap targets the AKT pathway, which is often overactive in PTEN‑deficient tumors. Abiraterone, on the other hand, reduces androgen levels – hormones that fuel prostate cancer growth. Prednisone helps manage side effects and supports the effectiveness of abiraterone.

By combining these medications, the treatment attacks cancer on multiple fronts:

1. Hormone suppression slows cancer growth.
2. AKT inhibition blocks cancer cell survival pathways.
3. Precision targeting ensures the therapy is used only in patients most likely to benefit.

This multi‑layered approach is why the combination has shown stronger results than hormone therapy alone.

Side Effects and Safety Considerations

Like most cancer treatments, Truqap can cause side effects. In the CAPItello‑281 trial, the most common reactions included:

• Skin rashes
• Diarrhea
• Fatigue
• High blood sugar
• Changes in lab values such as decreased hemoglobin or lymphocytes

Some side effects were severe, particularly rash and hyperglycemia. Because Truqap can raise blood sugar levels, patients may need regular monitoring of fasting glucose and hemoglobin A1c before and during treatment.

Doctors may adjust dosing or provide supportive care to help manage these effects.

How the Treatment Is Taken

Truqap is taken orally twice daily for four days, followed by three days off. This cycle repeats weekly. Abiraterone is taken daily, along with low‑dose prednisone. Patients must also continue androgen deprivation therapy or have had a prior orchiectomy.

This schedule may require careful planning, but many patients appreciate the convenience of an oral therapy compared with intravenous treatments.

What This Means for Patients and Families

For patients with PTEN‑deficient metastatic prostate cancer, the FDA approval of Truqap represents a meaningful new option. It offers:

• A targeted therapy designed specifically for their tumor biology
• A proven ability to delay disease progression
• A treatment approach guided by biomarker testing
• A new path forward in a disease subtype with historically limited options

Families and caregivers may also find reassurance in knowing that treatment decisions can now be more personalized, based on the unique characteristics of the cancer.

The Bigger Picture: Precision Medicine in Prostate Cancer

Truqap’s approval reflects a broader shift in cancer care. Instead of treating all prostate cancers the same way, doctors are increasingly using genetic and molecular information to tailor therapies.

This approach has already transformed treatment for other cancers, and prostate cancer is now catching up. As more biomarkers are identified and more targeted therapies are developed, patients will have access to increasingly personalized care.

The approval also underscores the importance of early and comprehensive testing. Identifying PTEN deficiency at diagnosis can help ensure patients receive the most effective treatment as soon as possible.

The FDA approval of Truqap marks a major advancement in the treatment of metastatic prostate cancer. By offering the first targeted therapy for PTEN‑deficient tumors, it opens the door to more personalized, effective care for thousands of patients each year.

While the treatment does come with side effects and requires careful monitoring, its ability to delay cancer progression represents a meaningful step forward. As research continues and more data emerge, Truqap may become a cornerstone therapy for this aggressive cancer subtype.

For now, patients and families can take hope in knowing that science is moving rapidly toward more precise and effective treatments – and that this approval is just the beginning.

Source

Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
https://www.astrazeneca.com/media-centre/press-releases/2026/truqap-approved-in-us-for-prostate-cancer.html